Clinical

Clinical
Anti-amyloid-β asset prioritized by Galimedix

Alzheimer’s digest – 2021 Alzheimer’s digest – 2021 Galimedix accelerating development for GAL-201 GAL-201 (Anti amyloid-β) – Galimedix Galimedix announced an accelerated program for its oral small molecule GAL-201 targeting amyloid-β oligomers Planning for FIH within one year In preclinical […]

by Sandhya Ramalingam

Continue Reading
Clinical
Anti-tau vaccine: Axon Neuroscience’s AADvac1

Alzheimer’s digest – 2021 Alzheimer’s digest – 2021 Axon Neuroscience published ADAMANT Phase 2 study of AAdvac1 AADvac1 (Alzheimer’s tau vaccine) – Axon Neuroscience Trial details: ADAMANT; Phase 2 in mild Alzheimer’s disease; N= 196; AADvac1 40 µg SC Q4W […]

by Sandhya Ramalingam

Continue Reading